Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) said it has temporarily paused production at its Freeman manufacturing facility in Worthing, West Sussex, in order to accelerate site improvements there.
The partial stop follows an internal review of current operating processes, investors were told.
Specifically, it is part of the group's previously communicated programme to improve the "robustness of its quality systems and build capacity across its production facilities", the company explained.
It also stressed that none of the areas for improvement are related to product safety and all of the group's clinical trials remain unaffected.
"This temporary pausing of production is a necessary step to ensure that we can both continue to deliver the highest standards of quality in our products and build capacity for the future growth of the group,” said chief executive Manuel Llobet.
“It does not affect the safety of our products. Our work to deliver ongoing improvements has identified a number of systems that require further optimisation.
“Accelerating this work will ensure Allergy Therapeutics is fit for the future across its growing portfolio.”